Salivary Biomarkers for Early Laryngeal Tissue Injury: Clinical Utility and Research Perspectives

Abstract

Laryngeal tissue injury represents a significant clinical challenge due to the critical role of the larynx in phonation, airway protection, and overall respiratory health. Early detection is pivotal for optimal intervention, yet current diagnostic modalities are often invasive or lack sensitivity for subtle, early-stage changes. Recent research has illuminated the potential of salivary biomarkers as non-invasive, sensitive tools for early detection of laryngeal tissue injury. This review examines the scientific evidence supporting salivary biomarker utility, explores their underlying mechanisms, and discusses their integration into clinical practice with a focus on emerging advances and guideline recommendations.

Introduction

Laryngeal tissue injury encompasses a spectrum of pathological changes arising from various insults such as phonotrauma, gastroesophageal reflux, inhalational exposures, and iatrogenic damage. Early diagnosis remains challenging, often relying on subjective assessment and invasive procedures like laryngoscopy. The search for objective, non-invasive diagnostic tools has driven interest in salivary biomarkers, given saliva's accessibility and its content of proteins, enzymes, cytokines, and molecular signatures reflective of laryngeal health. This article reviews the current landscape of salivary biomarkers in the context of early laryngeal tissue injury, synthesizing recent research and highlighting practical implications for clinicians.

Epidemiology / Disease Burden

Laryngeal injury is prevalent among individuals with high vocal demands, such as singers, teachers, and call center workers, as well as patients with chronic cough, reflux disease, and exposure to irritants. The global burden is significant, with voice disorders affecting up to 30% of the population at some point, leading to substantial morbidity, occupational disability, and reduced quality of life. Early tissue changes often precede overt clinical symptoms, underscoring the need for sensitive detection strategies to prevent progression to chronic laryngeal disease.

Pathophysiology

The pathogenesis of laryngeal tissue injury involves a complex interplay of mechanical, chemical, and inflammatory processes. Repeated phonotrauma disrupts epithelial integrity, leading to increased vascular permeability, subepithelial edema, and recruitment of inflammatory cells. Exposure to acidic refluxate or environmental toxins induces oxidative stress, cytokine release, and matrix metalloproteinase activation, resulting in extracellular matrix remodeling and mucosal damage. These processes manifest as alterations in local and systemic biomarker profiles, with saliva serving as a reservoir for detecting such molecular changes.

Risk Factors

Identifiable risk factors for laryngeal tissue injury include occupational or recreational vocal overuse, gastroesophageal reflux disease (GERD), smoking, inhalational allergen or irritant exposure, and systemic conditions such as autoimmune disorders. Contributory factors like dehydration, suboptimal vocal technique, and certain medications further compound vulnerability. Early identification of at-risk individuals is crucial for targeted monitoring and preventive strategies.

Clinical Features

Early laryngeal injury may be clinically silent or present with subtle symptoms such as transient hoarseness, vocal fatigue, globus sensation, or mild dysphonia. As injury progresses, symptoms can evolve into persistent hoarseness, loss of vocal range, throat pain, and cough. Standard clinical examination may not detect subclinical tissue changes, highlighting the need for adjunctive diagnostic modalities.

Diagnosis

Traditional diagnosis of laryngeal injury relies on history, physical examination, and visualization via flexible or rigid laryngoscopy. However, these approaches are limited in sensitivity for early or microscopic lesions and may be impractical for serial monitoring. Salivary biomarkers such as inflammatory cytokines (IL-6, TNF-α), matrix metalloproteinases, and oxidative stress markers have emerged as promising non-invasive indicators of early tissue injury. Studies demonstrate that elevated salivary IL-8 and MMP-9 levels correlate with acute laryngeal inflammation and vocal fold edema. Multiplex salivary assays enable simultaneous detection of multiple markers, offering enhanced diagnostic accuracy. Standardization of sample collection, processing, and interpretation remains a critical challenge for routine clinical adoption.

Treatment & Management

Management of early laryngeal injury is multifaceted, emphasizing risk factor modification, vocal hygiene education, and treatment of underlying etiologies such as reflux or allergic disease. Voice therapy, led by specialized speech-language pathologists, remains the cornerstone for functional recovery. Pharmacologic interventions may include proton pump inhibitors for reflux-induced injury or corticosteroids for inflammatory conditions. Integration of salivary biomarker monitoring could guide individualized management, allowing timely intervention and assessment of therapeutic response.

Recent Advances / Emerging Therapies

Recent advances in proteomics and transcriptomics have expanded the repertoire of candidate salivary biomarkers, including microRNAs and exosomal content, which reflect molecular events in laryngeal injury. Point-of-care diagnostic platforms utilizing immunoassay and biosensor technologies are being developed for rapid, chairside assessment. Emerging therapies in tissue engineering and regenerative medicine, such as growth factor delivery and stem cell-based approaches, may benefit from biomarker-guided monitoring to assess efficacy and safety in early-phase studies.

Guideline Recommendations

Current clinical guidelines emphasize early identification and multidisciplinary management of voice disorders and laryngeal injury. While salivary biomarkers are not yet incorporated into formal recommendations, expert consensus supports their potential as adjunctive tools for risk stratification and monitoring. Ongoing research and validation studies are necessary to establish standardized protocols and define cutoff values for clinical decision-making.

Conclusion

Salivary biomarkers represent a paradigm shift in the early detection and monitoring of laryngeal tissue injury, offering a non-invasive, scalable, and patient-friendly alternative to traditional diagnostic methods. While further research is warranted to validate specific biomarkers and integrate them into clinical practice, current evidence supports their promise for enhancing diagnostic precision, guiding individualized therapy, and improving outcomes in patients at risk for laryngeal injury. Clinicians should remain abreast of emerging data and advocate for the integration of biomarker-based strategies within multidisciplinary care pathways.